EICHORCondition: Non-small Cell Lung Cancer · Sponsor: Abramson Cancer Center at Penn Medicine
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.
This description comes directly from the study's public registry record.
Melissa Volpe, BA · 215-220-9703 · Melissa.volpe@pennmedicine.upenn.edu
Melina Marmarelis, MD · 267-438-8154
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older * Prior exposure to 4-6 cycles of Pem/Carbo/Pembro and PD after at least 18 weeks of maintenance Pemetrexed, Pembrolizumab or the combination of the two. * PS 0-1 Exclusion Criteria: * Presence of a driver mutation that is susceptible to targeted therapy * Other active invasive malignancy requiring ongoing therapy * Grade 2 or higher sensory neuropathy * Evidence of untreated brain metastases * History of bleeding diatheses or recent, antecedent hemoptysis (\> 1/2 teaspoon in prior 2 months)
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Abramson Cancer Center of the University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04332367